APO Research
Talk to an analyst

APO RESEARCH · REPORT

Dementia Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Dementia Drugs Market Analysis and Forecast 2026-2032

22 December 2025207 pages

Choose your research edition.

Industry ResearchDementia Drugs Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Dementia Drugs Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Dementia Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dementia Drugs Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Dementia Drugs Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Dementia Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Dementia Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Dementia Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Dementia Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Dementia Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Dementia Drugs include Janssen Pharmaceuticals, Inc, Eisai, Inc, Teva Pharmaceuticals Industries, Sanofi S.A, Johnson and Johnson, Novartis AG, Eli Lilly and Company, Pfizer Inc and Abbvie Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Dementia Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Dementia Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Dementia Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Dementia Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Dementia Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Dementia Drugs sales, projected growth trends, production technology, application and end-user industry.

Dementia Drugs Segment by Company

Janssen Pharmaceuticals, Inc

Eisai, Inc

Teva Pharmaceuticals Industries

Sanofi S.A

Johnson and Johnson

Novartis AG

Eli Lilly and Company

Pfizer Inc

Abbvie Inc

AstraZeneca GmbH

Zydus Cadila

Valeant Pharmaceutical International

Merck & Co., Inc

Forest Laboratories, Inc

F. Hoffmann-La Roche

Biogen Pharmaceuticals

Aurobindo Pharma

Apotex inc.

Dementia Drugs Segment by Type

Glutamate Inhibitors

Cholinesterase Inhibitors

MAO Inhibitors

Dementia Drugs Segment by Application

Hospital Pharmacies

Retail Pharmacies

Others

Dementia Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dementia Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dementia Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dementia Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Dementia Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Dementia Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Dementia Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Dementia Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Glutamate Inhibitors Major Manufacturers Table 3. Cholinesterase Inhibitors Major Manufacturers Table 4. MAO Inhibitors Major Manufacturers Table 5. Global Dementia Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital Pharmacies Major Manufacturers Table 7. Retail Pharmacies Major Manufacturers Table 8. Others Major Manufacturers Table 9. Dementia Drugs Industry Trends Table 10. Dementia Drugs Industry Drivers Table 11. Dementia Drugs Industry Opportunities and Challenges Table 12. Dementia Drugs Industry Restraints Table 13. Global Dementia Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Dementia Drugs Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Dementia Drugs Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Dementia Drugs Revenue Market Share by Region (2021-2026) Table 17. Global Dementia Drugs Revenue Market Share by Region (2027-2032) Table 18. Global Dementia Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 19. Global Dementia Drugs Sales by Region (2021-2026) & (k units) Table 20. Global Dementia Drugs Sales by Region (2027-2032) & (k units) Table 21. Global Dementia Drugs Sales Market Share by Region (2021-2026) Table 22. Global Dementia Drugs Sales Market Share by Region (2027-2032) Table 23. Global Dementia Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Dementia Drugs Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Dementia Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Dementia Drugs Sales Market Share by Manufacturers (2021-2026) Table 27. Global Dementia Drugs Sales Price (US$/unit) of Manufacturers (2021-2026) Table 28. Global Dementia Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Dementia Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Dementia Drugs Manufacturers, Product Type & Application Table 31. Global Dementia Drugs Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Dementia Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Dementia Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Dementia Drugs Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Dementia Drugs Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Dementia Drugs Revenue Market Share by Type (2021-2026) Table 38. Global Dementia Drugs Revenue Market Share by Type (2027-2032) Table 39. Global Dementia Drugs Sales by Type 2021 VS 2025 VS 2032 (k units) Table 40. Global Dementia Drugs Sales by Type (2021-2026) & (k units) Table 41. Global Dementia Drugs Sales by Type (2027-2032) & (k units) Table 42. Global Dementia Drugs Sales Market Share by Type (2021-2026) Table 43. Global Dementia Drugs Sales Market Share by Type (2027-2032) Table 44. Global Dementia Drugs Price by Type (2021-2026) & (US$/unit) Table 45. Global Dementia Drugs Price by Type (2027-2032) & (US$/unit) Table 46. Global Dementia Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Dementia Drugs Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Dementia Drugs Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Dementia Drugs Revenue Market Share by Application (2021-2026) Table 50. Global Dementia Drugs Revenue Market Share by Application (2027-2032) Table 51. Global Dementia Drugs Sales by Application 2021 VS 2025 VS 2032 (k units) Table 52. Global Dementia Drugs Sales by Application (2021-2026) & (k units) Table 53. Global Dementia Drugs Sales by Application (2027-2032) & (k units) Table 54. Global Dementia Drugs Sales Market Share by Application (2021-2026) Table 55. Global Dementia Drugs Sales Market Share by Application (2027-2032) Table 56. Global Dementia Drugs Price by Application (2021-2026) & (US$/unit) Table 57. Global Dementia Drugs Price by Application (2027-2032) & (US$/unit) Table 58. Janssen Pharmaceuticals, Inc Company Information Table 59. Janssen Pharmaceuticals, Inc Business Overview Table 60. Janssen Pharmaceuticals, Inc Dementia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Janssen Pharmaceuticals, Inc Dementia Drugs Product Portfolio Table 62. Janssen Pharmaceuticals, Inc Recent Development Table 63. Eisai, Inc Company Information Table 64. Eisai, Inc Business Overview Table 65. Eisai, Inc Dementia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Eisai, Inc Dementia Drugs Product Portfolio Table 67. Eisai, Inc Recent Development Table 68. Teva Pharmaceuticals Industries Company Information Table 69. Teva Pharmaceuticals Industries Business Overview Table 70. Teva Pharmaceuticals Industries Dementia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Teva Pharmaceuticals Industries Dementia Drugs Product Portfolio Table 72. Teva Pharmaceuticals Industries Recent Development Table 73. Sanofi S.A Company Information Table 74. Sanofi S.A Business Overview Table 75. Sanofi S.A Dementia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Sanofi S.A Dementia Drugs Product Portfolio Table 77. Sanofi S.A Recent Development Table 78. Johnson and Johnson Company Information Table 79. Johnson and Johnson Business Overview Table 80. Johnson and Johnson Dementia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Johnson and Johnson Dementia Drugs Product Portfolio Table 82. Johnson and Johnson Recent Development Table 83. Novartis AG Company Information Table 84. Novartis AG Business Overview Table 85. Novartis AG Dementia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Novartis AG Dementia Drugs Product Portfolio Table 87. Novartis AG Recent Development Table 88. Eli Lilly and Company Company Information Table 89. Eli Lilly and Company Business Overview Table 90. Eli Lilly and Company Dementia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Eli Lilly and Company Dementia Drugs Product Portfolio Table 92. Eli Lilly and Company Recent Development Table 93. Pfizer Inc Company Information Table 94. Pfizer Inc Business Overview Table 95. Pfizer Inc Dementia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Pfizer Inc Dementia Drugs Product Portfolio Table 97. Pfizer Inc Recent Development Table 98. Abbvie Inc Company Information Table 99. Abbvie Inc Business Overview Table 100. Abbvie Inc Dementia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Abbvie Inc Dementia Drugs Product Portfolio Table 102. Abbvie Inc Recent Development Table 103. AstraZeneca GmbH Company Information Table 104. AstraZeneca GmbH Business Overview Table 105. AstraZeneca GmbH Dementia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. AstraZeneca GmbH Dementia Drugs Product Portfolio Table 107. AstraZeneca GmbH Recent Development Table 108. Zydus Cadila Company Information Table 109. Zydus Cadila Business Overview Table 110. Zydus Cadila Dementia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Zydus Cadila Dementia Drugs Product Portfolio Table 112. Zydus Cadila Recent Development Table 113. Valeant Pharmaceutical International Company Information Table 114. Valeant Pharmaceutical International Business Overview Table 115. Valeant Pharmaceutical International Dementia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Valeant Pharmaceutical International Dementia Drugs Product Portfolio Table 117. Valeant Pharmaceutical International Recent Development Table 118. Merck & Co., Inc Company Information Table 119. Merck & Co., Inc Business Overview Table 120. Merck & Co., Inc Dementia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. Merck & Co., Inc Dementia Drugs Product Portfolio Table 122. Merck & Co., Inc Recent Development Table 123. Forest Laboratories, Inc Company Information Table 124. Forest Laboratories, Inc Business Overview Table 125. Forest Laboratories, Inc Dementia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 126. Forest Laboratories, Inc Dementia Drugs Product Portfolio Table 127. Forest Laboratories, Inc Recent Development Table 128. F. Hoffmann-La Roche Company Information Table 129. F. Hoffmann-La Roche Business Overview Table 130. F. Hoffmann-La Roche Dementia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 131. F. Hoffmann-La Roche Dementia Drugs Product Portfolio Table 132. F. Hoffmann-La Roche Recent Development Table 133. Biogen Pharmaceuticals Company Information Table 134. Biogen Pharmaceuticals Business Overview Table 135. Biogen Pharmaceuticals Dementia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 136. Biogen Pharmaceuticals Dementia Drugs Product Portfolio Table 137. Biogen Pharmaceuticals Recent Development Table 138. Aurobindo Pharma Company Information Table 139. Aurobindo Pharma Business Overview Table 140. Aurobindo Pharma Dementia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 141. Aurobindo Pharma Dementia Drugs Product Portfolio Table 142. Aurobindo Pharma Recent Development Table 143. Apotex inc. Company Information Table 144. Apotex inc. Business Overview Table 145. Apotex inc. Dementia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 146. Apotex inc. Dementia Drugs Product Portfolio Table 147. Apotex inc. Recent Development Table 148. North America Dementia Drugs Revenue by Type (2021-2026) & (US$ Million) Table 149. North America Dementia Drugs Revenue by Type (2027-2032) & (US$ Million) Table 150. North America Dementia Drugs Sales by Type (2021-2026) & (k units) Table 151. North America Dementia Drugs Sales by Type (2027-2032) & (k units) Table 152. North America Dementia Drugs Sales Price by Type (2021-2026) & (US$/unit) Table 153. North America Dementia Drugs Sales Price by Type (2027-2032) & (US$/unit) Table 154. North America Dementia Drugs Revenue by Application (2021-2026) & (US$ Million) Table 155. North America Dementia Drugs Revenue by Application (2027-2032) & (US$ Million) Table 156. North America Dementia Drugs Sales by Application (2021-2026) & (k units) Table 157. North America Dementia Drugs Sales by Application (2027-2032) & (k units) Table 158. North America Dementia Drugs Sales Price by Application (2021-2026) & (US$/unit) Table 159. North America Dementia Drugs Sales Price by Application (2027-2032) & (US$/unit) Table 160. North America Dementia Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 161. North America Dementia Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 162. North America Dementia Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 163. North America Dementia Drugs Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 164. North America Dementia Drugs Sales by Country (2021-2026) & (k units) Table 165. North America Dementia Drugs Sales by Country (2027-2032) & (k units) Table 166. North America Dementia Drugs Sales Price by Country (2021-2026) & (US$/unit) Table 167. North America Dementia Drugs Sales Price by Country (2027-2032) & (US$/unit) Table 168. United States Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 169. Canada Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 170. Mexico Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 171. Europe Dementia Drugs Revenue by Type (2021-2026) & (US$ Million) Table 172. Europe Dementia Drugs Revenue by Type (2027-2032) & (US$ Million) Table 173. Europe Dementia Drugs Sales by Type (2021-2026) & (k units) Table 174. Europe Dementia Drugs Sales by Type (2027-2032) & (k units) Table 175. Europe Dementia Drugs Sales Price by Type (2021-2026) & (US$/unit) Table 176. Europe Dementia Drugs Sales Price by Type (2027-2032) & (US$/unit) Table 177. Europe Dementia Drugs Revenue by Application (2021-2026) & (US$ Million) Table 178. Europe Dementia Drugs Revenue by Application (2027-2032) & (US$ Million) Table 179. Europe Dementia Drugs Sales by Application (2021-2026) & (k units) Table 180. Europe Dementia Drugs Sales by Application (2027-2032) & (k units) Table 181. Europe Dementia Drugs Sales Price by Application (2021-2026) & (US$/unit) Table 182. Europe Dementia Drugs Sales Price by Application (2027-2032) & (US$/unit) Table 183. Europe Dementia Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 184. Europe Dementia Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 185. Europe Dementia Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 186. Europe Dementia Drugs Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 187. Europe Dementia Drugs Sales by Country (2021-2026) & (k units) Table 188. Europe Dementia Drugs Sales by Country (2027-2032) & (k units) Table 189. Europe Dementia Drugs Sales Price by Country (2021-2026) & (US$/unit) Table 190. Europe Dementia Drugs Sales Price by Country (2027-2032) & (US$/unit) Table 191. Germany Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 192. France Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 193. U.K. Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 194. Italy Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 195. Russia Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 196. Spain Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 197. Netherlands Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 198. Switzerland Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 199. Sweden Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 200. Poland Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 201. China Dementia Drugs Revenue by Type (2021-2026) & (US$ Million) Table 202. China Dementia Drugs Revenue by Type (2027-2032) & (US$ Million) Table 203. China Dementia Drugs Sales by Type (2021-2026) & (k units) Table 204. China Dementia Drugs Sales by Type (2027-2032) & (k units) Table 205. China Dementia Drugs Sales Price by Type (2021-2026) & (US$/unit) Table 206. China Dementia Drugs Sales Price by Type (2027-2032) & (US$/unit) Table 207. China Dementia Drugs Revenue by Application (2021-2026) & (US$ Million) Table 208. China Dementia Drugs Revenue by Application (2027-2032) & (US$ Million) Table 209. China Dementia Drugs Sales by Application (2021-2026) & (k units) Table 210. China Dementia Drugs Sales by Application (2027-2032) & (k units) Table 211. China Dementia Drugs Sales Price by Application (2021-2026) & (US$/unit) Table 212. China Dementia Drugs Sales Price by Application (2027-2032) & (US$/unit) Table 213. Asia Dementia Drugs Revenue by Type (2021-2026) & (US$ Million) Table 214. Asia Dementia Drugs Revenue by Type (2027-2032) & (US$ Million) Table 215. Asia Dementia Drugs Sales by Type (2021-2026) & (k units) Table 216. Asia Dementia Drugs Sales by Type (2027-2032) & (k units) Table 217. Asia Dementia Drugs Sales Price by Type (2021-2026) & (US$/unit) Table 218. Asia Dementia Drugs Sales Price by Type (2027-2032) & (US$/unit) Table 219. Asia Dementia Drugs Revenue by Application (2021-2026) & (US$ Million) Table 220. Asia Dementia Drugs Revenue by Application (2027-2032) & (US$ Million) Table 221. Asia Dementia Drugs Sales by Application (2021-2026) & (k units) Table 222. Asia Dementia Drugs Sales by Application (2027-2032) & (k units) Table 223. Asia Dementia Drugs Sales Price by Application (2021-2026) & (US$/unit) Table 224. Asia Dementia Drugs Sales Price by Application (2027-2032) & (US$/unit) Table 225. Asia Dementia Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 226. Asia Dementia Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 227. Asia Dementia Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 228. Asia Dementia Drugs Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 229. Asia Dementia Drugs Sales by Country (2021-2026) & (k units) Table 230. Asia Dementia Drugs Sales by Country (2027-2032) & (k units) Table 231. Asia Dementia Drugs Sales Price by Country (2021-2026) & (US$/unit) Table 232. Asia Dementia Drugs Sales Price by Country (2027-2032) & (US$/unit) Table 233. Japan Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 234. South Korea Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 235. India Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 236. Australia Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 237. Taiwan Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 238. Southeast Asia Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 239. SAMEA Dementia Drugs Revenue by Type (2021-2026) & (US$ Million) Table 240. SAMEA Dementia Drugs Revenue by Type (2027-2032) & (US$ Million) Table 241. SAMEA Dementia Drugs Sales by Type (2021-2026) & (k units) Table 242. SAMEA Dementia Drugs Sales by Type (2027-2032) & (k units) Table 243. SAMEA Dementia Drugs Sales Price by Type (2021-2026) & (US$/unit) Table 244. SAMEA Dementia Drugs Sales Price by Type (2027-2032) & (US$/unit) Table 245. SAMEA Dementia Drugs Revenue by Application (2021-2026) & (US$ Million) Table 246. SAMEA Dementia Drugs Revenue by Application (2027-2032) & (US$ Million) Table 247. SAMEA Dementia Drugs Sales by Application (2021-2026) & (k units) Table 248. SAMEA Dementia Drugs Sales by Application (2027-2032) & (k units) Table 249. SAMEA Dementia Drugs Sales Price by Application (2021-2026) & (US$/unit) Table 250. SAMEA Dementia Drugs Sales Price by Application (2027-2032) & (US$/unit) Table 251. SAMEA Dementia Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 252. SAMEA Dementia Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 253. SAMEA Dementia Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 254. SAMEA Dementia Drugs Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 255. SAMEA Dementia Drugs Sales by Country (2021-2026) & (k units) Table 256. SAMEA Dementia Drugs Sales by Country (2027-2032) & (k units) Table 257. SAMEA Dementia Drugs Sales Price by Country (2021-2026) & (US$/unit) Table 258. SAMEA Dementia Drugs Sales Price by Country (2027-2032) & (US$/unit) Table 259. Brazil Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 260. Argentina Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 261. Chile Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 262. Colombia Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 263. Peru Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 264. Saudi Arabia Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 265. Israel Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 266. UAE Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 267. Turkey Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 268. Iran Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 269. Egypt Dementia Drugs Revenue (2021-2032) & (US$ Million) Table 270. Key Raw Materials Table 271. Raw Materials Key Suppliers Table 272. Dementia Drugs Distributors List Table 273. Dementia Drugs Customers List Table 274. Research Programs/Design for This Report Table 275. Authors List of This Report Table 276. Secondary Sources Table 277. Primary Sources List of Figures Figure 1. Dementia Drugs Image Figure 2. Global Dementia Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dementia Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Glutamate Inhibitors Image Figure 5. Cholinesterase Inhibitors Image Figure 6. MAO Inhibitors Image Figure 7. Global Dementia Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Dementia Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital Pharmacies Image Figure 10. Retail Pharmacies Image Figure 11. Others Image Figure 12. Global Dementia Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Dementia Drugs Revenue (2021-2032) & (US$ Million) Figure 14. Global Dementia Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Dementia Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Dementia Drugs Revenue Market Share by Region (2021-2032) Figure 17. Global Dementia Drugs Sales (2021-2032) & (k units) Figure 18. Global Dementia Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 19. Global Dementia Drugs Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Dementia Drugs Sales YoY (2021-2032) & (k units) Figure 21. Europe Dementia Drugs Sales YoY (2021-2032) & (k units) Figure 22. China Dementia Drugs Sales YoY (2021-2032) & (k units) Figure 23. Asia (Excluding China) Dementia Drugs Sales YoY (2021-2032) & (k units) Figure 24. South America, Middle East and Africa Dementia Drugs Sales YoY (2021-2032) & (k units) Figure 25. Global Dementia Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Dementia Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Dementia Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Dementia Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Dementia Drugs Revenue Market Share by Type (2021-2032) Figure 31. Global Dementia Drugs Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 32. Global Dementia Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Dementia Drugs Sales Market Share by Type (2021-2032) Figure 34. Global Dementia Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Dementia Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 36. Global Dementia Drugs Revenue Market Share by Application (2021-2032) Figure 37. Global Dementia Drugs Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 38. Global Dementia Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Dementia Drugs Sales Market Share by Application (2021-2032) Figure 40. North America Dementia Drugs Revenue Share by Type (2021-2032) Figure 41. North America Dementia Drugs Sales Share by Type (2021-2032) Figure 42. North America Dementia Drugs Revenue Share by Application (2021-2032) Figure 43. North America Dementia Drugs Sales Share by Application (2021-2032) Figure 44. North America Dementia Drugs Revenue Share by Country (2021-2032) Figure 45. North America Dementia Drugs Sales Share by Country (2021-2032) Figure 46. Europe Dementia Drugs Revenue Share by Type (2021-2032) Figure 47. Europe Dementia Drugs Sales Share by Type (2021-2032) Figure 48. Europe Dementia Drugs Revenue Share by Application (2021-2032) Figure 49. Europe Dementia Drugs Sales Share by Application (2021-2032) Figure 50. Europe Dementia Drugs Revenue Share by Country (2021-2032) Figure 51. Europe Dementia Drugs Sales Share by Country (2021-2032) Figure 52. China Dementia Drugs Revenue Share by Type (2021-2032) Figure 53. China Dementia Drugs Sales Share by Type (2021-2032) Figure 54. China Dementia Drugs Revenue Share by Application (2021-2032) Figure 55. China Dementia Drugs Sales Share by Application (2021-2032) Figure 56. Asia Dementia Drugs Revenue Share by Type (2021-2032) Figure 57. Asia Dementia Drugs Sales Share by Type (2021-2032) Figure 58. Asia Dementia Drugs Revenue Share by Application (2021-2032) Figure 59. Asia Dementia Drugs Sales Share by Application (2021-2032) Figure 60. Asia Dementia Drugs Revenue Share by Country (2021-2032) Figure 61. Asia Dementia Drugs Sales Share by Country (2021-2032) Figure 62. SAMEA Dementia Drugs Revenue Share by Type (2021-2032) Figure 63. SAMEA Dementia Drugs Sales Share by Type (2021-2032) Figure 64. SAMEA Dementia Drugs Revenue Share by Application (2021-2032) Figure 65. SAMEA Dementia Drugs Sales Share by Application (2021-2032) Figure 66. SAMEA Dementia Drugs Revenue Share by Country (2021-2032) Figure 67. SAMEA Dementia Drugs Sales Share by Country (2021-2032) Figure 68. Dementia Drugs Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Dementia Drugs Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Glutamate Inhibitors
  • Cholinesterase Inhibitors
  • MAO Inhibitors
Applications
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
Companies covered
  • Janssen Pharmaceuticals, Inc
  • Eisai, Inc
  • Teva Pharmaceuticals Industries
  • Sanofi S.A
  • Johnson and Johnson
  • Novartis AG
  • Eli Lilly and Company
  • Pfizer Inc
  • Abbvie Inc
  • AstraZeneca GmbH
  • Zydus Cadila
  • Valeant Pharmaceutical International
  • Merck & Co., Inc
  • Forest Laboratories, Inc
  • F. Hoffmann-La Roche
  • Biogen Pharmaceuticals
  • Aurobindo Pharma
  • Apotex inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Dementia Drugs Market by Type
  3. 1.2.1 Global Dementia Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Glutamate Inhibitors
  5. 1.2.3 Cholinesterase Inhibitors
  6. 1.2.4 MAO Inhibitors
  7. 1.3 Dementia Drugs Market by Application
  8. 1.3.1 Global Dementia Drugs Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital Pharmacies
  10. 1.3.3 Retail Pharmacies
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Dementia Drugs Market Dynamics
  1. 2.1 Dementia Drugs Industry Trends
  2. 2.2 Dementia Drugs Industry Drivers
  3. 2.3 Dementia Drugs Industry Opportunities and Challenges
  4. 2.4 Dementia Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Dementia Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Dementia Drugs Revenue by Region
  3. 3.2.1 Global Dementia Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Dementia Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Dementia Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Dementia Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Dementia Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Dementia Drugs Sales by Region
  9. 3.4.1 Global Dementia Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Dementia Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Dementia Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Dementia Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Dementia Drugs Revenue by Manufacturers
  2. 4.1.1 Global Dementia Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Dementia Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Dementia Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Dementia Drugs Sales by Manufacturers
  6. 4.2.1 Global Dementia Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Dementia Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Dementia Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Dementia Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Dementia Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Dementia Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Dementia Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Dementia Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Dementia Drugs Market CR5 and HHI
  16. 4.8.2 2025 Dementia Drugs Tier 1, Tier 2, and Tier 3
5 Dementia Drugs Market by Type
  1. 5.1 Global Dementia Drugs Revenue by Type
  2. 5.1.1 Global Dementia Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Dementia Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Dementia Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Dementia Drugs Sales by Type
  6. 5.2.1 Global Dementia Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Dementia Drugs Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Dementia Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Dementia Drugs Price by Type
6 Dementia Drugs Market by Application
  1. 6.1 Global Dementia Drugs Revenue by Application
  2. 6.1.1 Global Dementia Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Dementia Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Dementia Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Dementia Drugs Sales by Application
  6. 6.2.1 Global Dementia Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Dementia Drugs Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Dementia Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Dementia Drugs Price by Application
7 Company Profiles
  1. 7.1 Janssen Pharmaceuticals, Inc
  2. 7.1.1 Janssen Pharmaceuticals, Inc Company Information
  3. 7.1.2 Janssen Pharmaceuticals, Inc Business Overview
  4. 7.1.3 Janssen Pharmaceuticals, Inc Dementia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Janssen Pharmaceuticals, Inc Dementia Drugs Product Portfolio
  6. 7.1.5 Janssen Pharmaceuticals, Inc Recent Developments
  7. 7.2 Eisai, Inc
  8. 7.2.1 Eisai, Inc Company Information
  9. 7.2.2 Eisai, Inc Business Overview
  10. 7.2.3 Eisai, Inc Dementia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Eisai, Inc Dementia Drugs Product Portfolio
  12. 7.2.5 Eisai, Inc Recent Developments
  13. 7.3 Teva Pharmaceuticals Industries
  14. 7.3.1 Teva Pharmaceuticals Industries Company Information
  15. 7.3.2 Teva Pharmaceuticals Industries Business Overview
  16. 7.3.3 Teva Pharmaceuticals Industries Dementia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Teva Pharmaceuticals Industries Dementia Drugs Product Portfolio
  18. 7.3.5 Teva Pharmaceuticals Industries Recent Developments
  19. 7.4 Sanofi S.A
  20. 7.4.1 Sanofi S.A Company Information
  21. 7.4.2 Sanofi S.A Business Overview
  22. 7.4.3 Sanofi S.A Dementia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Sanofi S.A Dementia Drugs Product Portfolio
  24. 7.4.5 Sanofi S.A Recent Developments
  25. 7.5 Johnson and Johnson
  26. 7.5.1 Johnson and Johnson Company Information
  27. 7.5.2 Johnson and Johnson Business Overview
  28. 7.5.3 Johnson and Johnson Dementia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Johnson and Johnson Dementia Drugs Product Portfolio
  30. 7.5.5 Johnson and Johnson Recent Developments
  31. 7.6 Novartis AG
  32. 7.6.1 Novartis AG Company Information
  33. 7.6.2 Novartis AG Business Overview
  34. 7.6.3 Novartis AG Dementia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Novartis AG Dementia Drugs Product Portfolio
  36. 7.6.5 Novartis AG Recent Developments
  37. 7.7 Eli Lilly and Company
  38. 7.7.1 Eli Lilly and Company Company Information
  39. 7.7.2 Eli Lilly and Company Business Overview
  40. 7.7.3 Eli Lilly and Company Dementia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Eli Lilly and Company Dementia Drugs Product Portfolio
  42. 7.7.5 Eli Lilly and Company Recent Developments
  43. 7.8 Pfizer Inc
  44. 7.8.1 Pfizer Inc Company Information
  45. 7.8.2 Pfizer Inc Business Overview
  46. 7.8.3 Pfizer Inc Dementia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Pfizer Inc Dementia Drugs Product Portfolio
  48. 7.8.5 Pfizer Inc Recent Developments
  49. 7.9 Abbvie Inc
  50. 7.9.1 Abbvie Inc Company Information
  51. 7.9.2 Abbvie Inc Business Overview
  52. 7.9.3 Abbvie Inc Dementia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Abbvie Inc Dementia Drugs Product Portfolio
  54. 7.9.5 Abbvie Inc Recent Developments
  55. 7.10 AstraZeneca GmbH
  56. 7.10.1 AstraZeneca GmbH Company Information
  57. 7.10.2 AstraZeneca GmbH Business Overview
  58. 7.10.3 AstraZeneca GmbH Dementia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 AstraZeneca GmbH Dementia Drugs Product Portfolio
  60. 7.10.5 AstraZeneca GmbH Recent Developments
  61. 7.11 Zydus Cadila
  62. 7.11.1 Zydus Cadila Company Information
  63. 7.11.2 Zydus Cadila Business Overview
  64. 7.11.3 Zydus Cadila Dementia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Zydus Cadila Dementia Drugs Product Portfolio
  66. 7.11.5 Zydus Cadila Recent Developments
  67. 7.12 Valeant Pharmaceutical International
  68. 7.12.1 Valeant Pharmaceutical International Company Information
  69. 7.12.2 Valeant Pharmaceutical International Business Overview
  70. 7.12.3 Valeant Pharmaceutical International Dementia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Valeant Pharmaceutical International Dementia Drugs Product Portfolio
  72. 7.12.5 Valeant Pharmaceutical International Recent Developments
  73. 7.13 Merck & Co., Inc
  74. 7.13.1 Merck & Co., Inc Company Information
  75. 7.13.2 Merck & Co., Inc Business Overview
  76. 7.13.3 Merck & Co., Inc Dementia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Merck & Co., Inc Dementia Drugs Product Portfolio
  78. 7.13.5 Merck & Co., Inc Recent Developments
  79. 7.14 Forest Laboratories, Inc
  80. 7.14.1 Forest Laboratories, Inc Company Information
  81. 7.14.2 Forest Laboratories, Inc Business Overview
  82. 7.14.3 Forest Laboratories, Inc Dementia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Forest Laboratories, Inc Dementia Drugs Product Portfolio
  84. 7.14.5 Forest Laboratories, Inc Recent Developments
  85. 7.15 F. Hoffmann-La Roche
  86. 7.15.1 F. Hoffmann-La Roche Company Information
  87. 7.15.2 F. Hoffmann-La Roche Business Overview
  88. 7.15.3 F. Hoffmann-La Roche Dementia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 F. Hoffmann-La Roche Dementia Drugs Product Portfolio
  90. 7.15.5 F. Hoffmann-La Roche Recent Developments
  91. 7.16 Biogen Pharmaceuticals
  92. 7.16.1 Biogen Pharmaceuticals Company Information
  93. 7.16.2 Biogen Pharmaceuticals Business Overview
  94. 7.16.3 Biogen Pharmaceuticals Dementia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Biogen Pharmaceuticals Dementia Drugs Product Portfolio
  96. 7.16.5 Biogen Pharmaceuticals Recent Developments
  97. 7.17 Aurobindo Pharma
  98. 7.17.1 Aurobindo Pharma Company Information
  99. 7.17.2 Aurobindo Pharma Business Overview
  100. 7.17.3 Aurobindo Pharma Dementia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Aurobindo Pharma Dementia Drugs Product Portfolio
  102. 7.17.5 Aurobindo Pharma Recent Developments
  103. 7.18 Apotex inc.
  104. 7.18.1 Apotex inc. Company Information
  105. 7.18.2 Apotex inc. Business Overview
  106. 7.18.3 Apotex inc. Dementia Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Apotex inc. Dementia Drugs Product Portfolio
  108. 7.18.5 Apotex inc. Recent Developments
8 North America
  1. 8.1 North America Dementia Drugs Market Size by Type
  2. 8.1.1 North America Dementia Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Dementia Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Dementia Drugs Price by Type (2021-2032)
  5. 8.2 North America Dementia Drugs Market Size by Application
  6. 8.2.1 North America Dementia Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Dementia Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Dementia Drugs Price by Application (2021-2032)
  9. 8.3 North America Dementia Drugs Market Size by Country
  10. 8.3.1 North America Dementia Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Dementia Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Dementia Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Dementia Drugs Market Size by Type
  2. 9.1.1 Europe Dementia Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Dementia Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Dementia Drugs Price by Type (2021-2032)
  5. 9.2 Europe Dementia Drugs Market Size by Application
  6. 9.2.1 Europe Dementia Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Dementia Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Dementia Drugs Price by Application (2021-2032)
  9. 9.3 Europe Dementia Drugs Market Size by Country
  10. 9.3.1 Europe Dementia Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Dementia Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Dementia Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Dementia Drugs Market Size by Type
  2. 10.1.1 China Dementia Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Dementia Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Dementia Drugs Price by Type (2021-2032)
  5. 10.2 China Dementia Drugs Market Size by Application
  6. 10.2.1 China Dementia Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Dementia Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Dementia Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Dementia Drugs Market Size by Type
  2. 11.1.1 Asia Dementia Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Dementia Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Dementia Drugs Price by Type (2021-2032)
  5. 11.2 Asia Dementia Drugs Market Size by Application
  6. 11.2.1 Asia Dementia Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Dementia Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Dementia Drugs Price by Application (2021-2032)
  9. 11.3 Asia Dementia Drugs Market Size by Country
  10. 11.3.1 Asia Dementia Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Dementia Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Dementia Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Dementia Drugs Market Size by Type
  2. 12.1.1 SAMEA Dementia Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Dementia Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Dementia Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Dementia Drugs Market Size by Application
  6. 12.2.1 SAMEA Dementia Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Dementia Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Dementia Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Dementia Drugs Market Size by Country
  10. 12.3.1 SAMEA Dementia Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Dementia Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Dementia Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Dementia Drugs Value Chain Analysis
  2. 13.1.1 Dementia Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Dementia Drugs Production Mode & Process
  6. 13.2 Dementia Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Dementia Drugs Distributors
  9. 13.2.3 Dementia Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst